Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 06, 2016 8:51 PM ET


Company Overview of Par Pharmaceutical Companies Inc.

Company Overview

Par Pharmaceutical Companies, Inc. develops, licenses, manufactures, markets, and distributes generic drugs in the United States. It operates through two segments, Par Pharmaceutical and Par Specialty Pharmaceuticals. The Par Pharmaceutical segment markets generic products under Par Pharmaceutical brand name and sterile products under the Par Sterile brand. This segment also offers dosage forms and delivery systems, including oral solids and alternate dosage forms, such as oral solids, injectables, topicals, nasal sprays, ophthalmics, films, and transdermal patches. In addition, this segment markets pharmaceutical products, including Exforge, Lovaza, Precedex, Lamictal XR, Luvox CR, and Foca...

One Ram Ridge Road

Chestnut Ridge, NY 10977

United States

Founded in 1978

1,600 Employees



Key Executives for Par Pharmaceutical Companies Inc.

Chief Executive Officer and Director
Age: 53
Chief Financial Officer, Executive Vice President, Treasurer and Director
Age: 57
Chief Operating Officer
Age: 49
Senior Vice President and General Counsel of Generics
Chief Commercial Officer
Age: 58
Compensation as of Fiscal Year 2015.

Par Pharmaceutical Companies Inc. Key Developments

Supernus Announces Settlement with Par Pharmaceutical Companies and Par Pharmaceutical on Trokendi XR Patent Litigation

Supernus Pharmaceuticals, Inc. announced that it has entered into a settlement agreement with Par Pharmaceutical Companies, Inc. and Par Pharmaceutical, Inc. involving the ongoing patent litigation regarding Par's filing of an Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Supernus' Trokendi XR® (extended-release topiramate) capsules. The settlement permits Par to begin selling a generic version of Trokendi XR® on April 1, 2025, or earlier under certain circumstances. The agreement is subject to entry of a consent judgment by the U.S. District Court for the District of New Jersey. In the consent judgment, Par acknowledges that the Orange Book-listed patents for Trokendi XR® owned by Supernus, namely United States Patent Nos. 8,298,576, 8,298,580, 8,663,683, 8,877,248, 8,889,191, and 8,992,989, are valid and enforceable with respect to Par's ANDA product, and would be infringed by Par's ANDA product. The agreement will be submitted to the applicable governmental agencies. The patent litigation continues against Actavis and Zydus, the other two ANDA filers. Patent protection for Trokendi XR® expires no earlier than 2027 and Supernus intends to continue its vigorous enforcement of its patent rights.

Par Pharmaceutical Begins Shipment of Generic Androgel® 1%

Par Pharmaceutical announced that it has begun shipping testosterone gel 1%. The U.S. Food and Drug Administration previously approved Par's Abbreviated New Drug Application for the product. Testosterone gel 1% is the generic version of AbbVie's AndroGel® 1% and is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Par previously entered into a settlement and license agreement and consent decree that permit Par to launch the product at this time, which is five years earlier than the expiration of the relevant patent. Testosterone gel 1% is available in 2.5 g and 5 g aluminum foil packets containing 25 mg or 50 mg testosterone, respectively. According to IMS Health data, annual U.S. sales of testosterone gel 1% packets are approximately $206 million. Testosterone gel 1% is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate. Testosterone gel 1% is contraindicated in women who are or may become pregnant, or who are breast feeding. Testosterone gel 1% may cause fetal harm when administered to a pregnant woman. Testosterone gel 1% may cause serious adverse reactions in nursing infants. Exposure of a female fetus or nursing infant to androgens may result in varying degrees of virilization. Pregnant women or those who may become pregnant need to be aware of the potential for transfer of testosterone from men treated with testosterone gel 1%. If a pregnant woman is exposed to testosterone gel 1%, she should be apprised of the potential hazard to the fetus. A black box warning for secondary exposure to testosterone is associated with this product.

Par Pharmaceutical Begins Shipment of Generic Sodium Edecrin

Par Pharmaceutical announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for ethacrynate sodium for injection USP, equivalent to ethacrynic acid 50 mg. Ethacrynate sodium is the generic version of Aton Pharma's Sodium Edecrin® and is used in the treatment of edema. Par's ethacrynate sodium for injection USP, 50 mg is the first and only generic available. Par has begun shipping ethacrynate sodium for injection USP, which is packaged in cartons of one 50 mg single-dose vial. According to IMS Health data, annual U.S. sales of Sodium Edecrin® are approximately $40 million.

Similar Private Companies By Industry

Company Name Region
Systemic Formulas, Inc. United States
ISW Group, Inc. United States
Medpace Medical Device, Inc. United States
Wasatch Pharmaceutical Inc. United States
Washburn Therapeutics, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Par Pharmaceutical Companies Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at